TAAT Provides Update on Status of MCTO

Rhea-AI Summary

TAAT Global Alternatives Inc. (OTCQX: TOBAF) announced an update regarding a management cease trade order issued on March 1, 2023, by the British Columbia Securities Commission due to delayed financial filings. The company is currently progressing with its audit and expects to provide an update on the filing of its Annual Filings by March 24, 2023. While the general public can trade TAAT's shares, the CEO and CFO are restricted from trading during this period. TAAT confirms compliance with reporting requirements and will provide bi-weekly updates until the matter is resolved.

Positive

• Audit progress is reported, indicating potential timely resolution of financial filing delays.

Negative

• Management cease trade order reflects regulatory scrutiny and ongoing issues with timely financial reporting.

LAS VEGAS and VANCOUVER, British Columbia, March 15, 2023 (GLOBE NEWSWIRE) -- TAAT^® GLOBAL ALTERNATIVES INC. (CSE: TAAT) (OTCQX: TOBAF) (FRANKFURT: 2TP) (the “Company” or “TAAT^®”) is providing this update on the status of a management cease trade order granted on March 1, 2023 (the "MCTO") by the British Columbia Securities Commission under National Policy 12-203 – Management Cease Trade Order ("NP 12-203"). On March 1, 2023, the Company announced that, for reasons disclosed in the news release, there would be a delay in the filing of its financial statements and accompanying management’s discussion and analysis for the fiscal year ended October 31, 2022 (the "Annual Filings") beyond the period prescribed under applicable Canadian securities laws (the "Default Announcement").

The Company reports that the audit is progressing and a further update on the timing of the filing of the Annual Filings is anticipated to occur on or about March 24, 2023. Further updates on timing will be provided by the Company as necessary.

During the MCTO, the general investing public will continue to be able to trade in the Company's listed common shares. However, the Company's Chief Executive Officer and Chief Financial Officer will not be able to trade in the Company's common shares.

Other than as disclosed in this news release, there are no material changes to the information contained in the Default Announcement. The Company confirms that it intends to satisfy the provisions of NP 12- 203 and will continue to issue bi-weekly default status reports for so long as it remains in default of the Annual Filings requirement.

On behalf of the Board of Directors of the Company,

TAAT^® GLOBAL ALTERNATIVES INC.

“Michael Saxon”

Michael Saxon, CEO and Director

For further information, please contact:

TAAT^® Investor Relations
1-833-TAAT-USA (1-833-822-8872)
investor@taatglobal.com

THE CANADIAN SECURITIES EXCHANGE (“CSE”) HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE, NOR HAS OR DOES THE CSE’S REGULATION SERVICES PROVIDER.

About TAAT^® Global Alternatives Inc.

TAAT^® is a vertically integrated consumer product and distribution company, generating more than CAD $90 million in overall gross revenue annually. TAAT^® is strategically expanding its product categories including tobacco and reduced-risk alternatives, hemp, kratom, and other emerging CPG segments. TAAT^® has facilities to include a processing plant in Nevada as well as a distribution centre in Canton, Ohio, leveraging existing retail shelf space and pipelines into national wholesale channels.

For more information, please visit http://taatglobal.com.

Forward-Looking Statements

Certain information contained herein may constitute "forward-looking information" or "forward-looking statements" under Canadian securities legislation. Generally, forward-looking information can be identified by words such as "pro forma", "plans", "expects", "may", "should", "could", "will", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", "believes", or variations including negative variations thereof of such words and phrases that refer to certain actions, events or results that may, occur or be taken or achieved. Such forward-looking statements, including but not limited to statements relating to the expected development and operations of the Company, statements concerning the timing, review, completion and filing of the Annual Filings as well as the duration of the MCTO, involve risks, uncertainties and other factors which may cause the actual results to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. The Corporation will not update any forward-looking statements or forward-looking information included herein, except as required by applicable securities laws.

The statements in this news release have not been evaluated by Health Canada or the U.S. Food and Drug Administration. As each individual is different, the benefits, if any, of taking the Company’s products will vary from person to person. No claims or guarantees can be made as to the effects of the Company’s products on an individual’s health and well-being. The Company’s products are not intended to diagnose, treat, cure, or prevent any disease.

This news release may contain trademarked names of third-party entities (or their respective offerings with trademarked names) typically in reference to (i) relationships had by the Company with such third-party entities as referred to in this release and/or (ii) client/vendor/service provider parties whose relationship with the Company is/are referred to in this release. All rights to such trademarks are reserved by their respective owners or licensees.

Statement Regarding Third-Party Investor Relations Firms

Disclosures relating to investor relations firms retained by TAAT^® Global Alternatives Inc. can be found under the Company's profile on http://sedar.com.

FAQ

What is the status of the management cease trade order for TAAT (TOBAF)?

TAAT is currently under a management cease trade order due to delayed financial filings, with an update expected around March 24, 2023.

Can the public trade TAAT (TOBAF) shares during the management cease trade order?

Yes, the general investing public can continue to trade TAAT's common shares, but the CEO and CFO are restricted.

When will TAAT (TOBAF) file its annual financial statements?

TAAT anticipates providing an update on the timing of its annual financial statements by March 24, 2023.

What financial impact does the management cease trade order have on TAAT (TOBAF)?

The cease trade order may create investor uncertainty and reflect ongoing issues with compliance and financial reporting.